TruScreen Annual Meeting of Shareholders- Results

NZX and Media Release 27 September 2018
NZX Limited
WELLINGTON
TruScreen Limited
Results of Annual Shareholder Meeting

The TruScreen Limited (NZAX: TRU) Annual Meeting of shareholders was held on 27 September
2018.
The company updated shareholders on its positive performance in the year to date as it continues to
make good commercial progress in its target markets, increase sales and expand its global footprint.
A number of large scale evaluations are underway in China and the company has commenced an
evaluation for TruScreen in Africa with the National Aids Council of Zimbabwe. Sales of both the
TruScreen device and single use sensors are tracking well ahead of last year, with ongoing demand
from China and other markets.
Voting was conducted by poll of the shareholders present at the meeting and the proxies registered.
Details of the resolutions and voting results were:

Resolution For Against Abstain
Authorise Directors to fix the auditor’s
remuneration: Passed
166,940,051
99.97%
50,000
0.03%
94,946

Re-election of Mr Robert Hunter as a
Director: Passed
142,235,926
89.38%
17,738,625
10.62%%
110,446

Election of Professor Ronald Jones as a
Director: Passed
108,719,551
99.72%
300,000
0.28%
58,065,446

Election of Mr Chris Lawrence as a
Director: Passed
108,719,551
99.72%
300,000
0.28%
58,065,446

Election of Ms Marie Ficarra as a Director: Withdrawn
Election of Mr Kelly (Con) Hickey as a
Director: Passed
108,448,551
99.49%
560,000
0.51%
58,065,446

Election of Mr Anthony Ho as a Director:
Passed
108,449,551
99.49%
560,000
0.51%
58,075,446


In accordance with the NZAX listing rule 3.2.1, three directors, Ron Jones, Chris Lawrence and Kelly
(Con) Hickey, are ordinarily resident in New Zealand.
ENDS
For more information visit www.truscreen.com

Contact

Martin Dillon
TruScreen Chief Executive Officer
Email: martindillon@truscreen.com



About TruScreen:
TruScreen’s real time cervical cancer technology
utilises a digital wand which is placed on the
surface of the cervix to measure electrical and
optical signals from the surrounding tissue. A
sophisticated proprietary algorithm framework
distinguishes between normal and abnormal
(cancerous and precancerous) tissue to identify
precancerous change, or cervical intraepithelial
neoplasia (CIN). A Single Use Sensor (SUS) is used
for each patient to protect against cross-infection.